OSD 2026: can disrupted stability in tumour tissue be measured?

Abstract and nature of the evidence

The study translates the hypothesis of a disrupted tumour-tissue repair regime into a score based on expression modules. The manuscript reports a retrospective computational evaluation of existing datasets, not a prospective clinical study or a laboratory-demonstrated therapeutic intervention.

A falsifiable hypothesis

Organism Stability Disruption (OSD) describes a hypothetical axis contrasting sustained tissue stress with the capacity to restore differentiated organisation. It is neither a new definition of cancer nor a claim of a universal cure. It offers a way to translate established biological processes—from inflammation to hypoxia and extracellular-matrix disruption—into testable modules.

Constructing a research indicator

OSD is defined as instability load minus order capacity. Its instability modules include inflammatory alarm, interferon alarm, wound/ECM/fibrosis, complement and coagulation, hypoxia/redox stress, and proteostasis/ER stress. Countervailing modules include polarity, cell adhesion, circadian order, mitochondrial homeostasis and differentiation. A separate residual score is obtained after statistically accounting for the proliferation signal.

The data underlying the analysis

The author's manuscript lists TCGA/GTEx for comparisons between tumours and corresponding normal tissue, TCGA PanCancer Atlas for survival, PanImmune and CIBERSORT for immune-component estimates, CPTAC proteogenomics, DepMap CRISPR dependencies, PRISM drug response, LINCS/L1000 perturbations, and further treatment cohorts including IMvigor210. These sources serve different purposes; combining them does not automatically constitute independent experimental validation.

Results and effect sizes

According to the author's manuscript, raw OSD was higher in tumours than in corresponding normal samples at 11 of 13 tissue sites, and at 9 of 13 after statistically accounting for proliferation. Among 8,893 primary tumours with survival data, residual OSD was associated with worse overall survival: the hazard ratio was 1.110 per standard deviation, with p = 1.50 × 10⁻⁷ in a cancer-type-stratified Cox model. Signal strength nevertheless varied by cancer type and comparison.

Why this does not yet establish a biomarker

Bulk expression data mix tumour, stromal and immune cells. The result may partly reflect tissue composition and other confounders. A retrospective prognostic association is not evidence of causality. Further work therefore requires independent-cohort validation, spatially or cellularly resolved measurements, and preregistered hypotheses.

Methodological controls and independent validation

Residualisation against proliferation is particularly important: without it, a composite score could largely reproduce information about cell division. Alongside tumour–non-tumour comparisons, the manuscript examines the relationship between the residual score and overall survival in a cohort of 8,893 primary tumours with available survival annotations.

The reported associations do not establish causality. Assessing clinical utility requires independent evaluation in external cohorts, comparison with conventional prognostic models, consideration of sample cellular composition, and biological testing of the proposed mechanisms.

An experiment that could advance the hypothesis

In the proposed perturbation–rechallenge procedure, researchers would target selected OSD modules, measure their recovery trajectories, and assess retention of the change after a second challenge. Such an experiment could distinguish genuine tissue-state dynamics from correlations across samples. Claims of therapeutic reset or clinical utility for OSD are not yet supported.

Read also

An introduction to OSD →

The opening graphic is a conceptual thematic illustration, not an experimental record.